COST MINIMIZATION ANALYSIS OF ADVANCED GASTRIC CANCER TREATMENT WITH CAPECITABINE/CISPLATIN (XP) VS. 5-FU/CISPLATIN (FP) REGIMENS IN POLISH SETTING

被引：0
|
作者：
Kawalec, P. [1 ]
Szawlowski, A. [2 ,3 ]
Federowicz, I [2 ,3 ]
Szkultecka-Debek, M. [4 ]
Russel-Szymczyk, M. [4 ]
机构：
[1] Centrum HTA, Krakow, Poland
[2] M Sklodowska Curie Mem Canc Ctr, Warsaw, Poland
[3] Inst Oncol, Warsaw, Poland
[4] Roche Polska, Warsaw, Poland
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)66580-1
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A473 / A473
页数：1
相关论文
共 50 条
  • [31] Efficacy of trastuzumab in combination with capecitabine and cisplatin vs 5-FU and cisplatin therapy for Korean patients with HER2-positive advanced gastric cancer Health Insurance Review and Assessment service (HIRA) data retrospective analysis
    Lee, Hyun Woo
    Kim, Jang-Hee
    Kang, Seok Yun
    Park, Tae Jun
    Choi, Yong Won
    [J]. CANCER RESEARCH, 2024, 84 (06)
  • [32] Phase I Irinotecan, Cisplatin and protracted infusion 5-FU (ICF) in advanced gastric cancer (AGC)
    Fernandez Martos, Carlos
    Segura, Angel
    Aparicio, Jorge
    Molins, Carmen
    Busquier, Isabel
    Poveda, Andres
    Balcells, Miquel
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 238 - 238
  • [33] A PHASE-II TRIAL OF 5-FU, ADRIAMYCIN AND CISPLATIN (FAP) IN ADVANCED GASTRIC-CANCER
    WOOLLEY, P
    SMITH, F
    ESTEVEZ, R
    GISSELBRECHT, C
    ALVAREZ, C
    BOIRON, M
    MACHADO, C
    LAGARDE, C
    SCHEIN, P
    [J]. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1981, 22 (MAR): : 455 - 455
  • [34] Phase II study of paclitaxel, cisplatin, and 5-FU combination chemotherapy in patients with advanced gastric cancer
    Cho, S.
    Shim, H.
    Lee, S.
    Ahn, J.
    Yang, D.
    Kim, Y.
    Park, C.
    Lee, J.
    Chung, I.
    Kim, H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [35] Pharmacogenetics of extraordinary responses to 5-FU/cisplatin chemotherapy in advanced gastric cancer - Report of 2 cases
    Wolschke, C
    Goekkurt, E
    Al-Batran, SE
    Hossfeld, DK
    Stoehlmacher, J
    [J]. ONKOLOGIE, 2005, 28 (11): : 589 - 592
  • [36] Preliminary cost-consequence analysis of epirubicin/cisplatin/5FU (ECF) compared to epirubicin/cisplatin/capecitabine (ECX) in patients with advanced oesophagogastric cancer
    Horgan, A. M.
    Knox, J.
    Liu, G.
    Bradbury, P. A.
    Sahi, C.
    Leighl, N. B.
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A65 - A65
  • [37] Efficacy and feasibility of paclitaxel and cisplatin combination chemotherapy for the treatment of 5-flurouracil (5-FU), doxorubicin refractory advanced gastric cancer
    Kim, Y.
    Prrk, B.
    Seo, J.
    Gang, J.
    Lee, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [38] Cost of caring patients with colorectal cancer with capecitabine vs 5-fu based regimens: Preliminary results of a naturalistic study
    De Purtu, S.
    Mantovani, L. G.
    Tamburini, E.
    Bollina, R.
    Grimaldi, A. M.
    Carten, G.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : 188 - 188
  • [39] New Perspectives in the Treatment of Advanced Gastric Cancer: S-1 as a Novel Oral 5-FU Therapy in Combination with Cisplatin
    Mahlberg, Rolf
    Lorenzen, Sylvie
    Thuss-Patience, Peter
    Heinemann, Volker
    Pfeiffer, Per
    Mohler, Markus
    [J]. CHEMOTHERAPY, 2017, 62 (01): : 62 - 70
  • [40] SALVAGE TREATMENT WITH CISPLATIN (CDDP) AND 5-FLUOROURACIL (5-FU) IN ADVANCED BREAST-CANCER PATIENTS
    PRONZATO, P
    AMOROSO, D
    BERTELLI, G
    LIONETTO, R
    ARDIZZONI, A
    CONTE, PF
    ROSSO, R
    GALLOTTI, P
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1987, 10 (01) : 108 - 108
12345